Alcoholic liver disease

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
7 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
A Gastroenterology (ATC A) 1
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
GLP-1 receptor agonist 1 substance
Erythropoietin analogue 1 substance
Statin 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Opella Healthcare Group S.A.S. Commercial
    DE-OILED ENRICHED PHOSPHOLIPIDS FROM SOYA-BEANS; PHOSPHATIDYL CHOLINE
    2025-521678-32-00 3 countries 2026 n=466
    Recruiting

Phase II/III

1 trial
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    SIMVASTATIN
    2024-519968-41-00 1 country 2024 n=90
    Recruiting

Phase II

1 trial
  • Novo Nordisk A/S Commercial
    CAGRILINTIDE; CAGRILINTIDE, SEMAGLUTIDE; SEMAGLUTIDE; ZALFERMIN
    2023-508170-28-00 10 countries 2024 n=140
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novo Nordisk A/S Commercial 1 Phase II 0
Opella Healthcare Group S.A.S. Commercial 1 Phase III 1
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase II/III 1
New trials by year
2024
2
2026
1
← All indication landscapes